Stephen Scholand, MD
Infectious Disease · Meriden, CTNPI 1679500268
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $326,716 of the $428,328 with a category attached, or 76.3%. Grifols USA, LLC accounts for 85.3% of it on its own, with 5 other manufacturers making up the rest. Among infectious disease clinicians in CT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 629 payments — averaging $680.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Grifols USA, LLC$365K
- Sanofi Pasteur Inc.$49K
- Pfizer$13K
- Grifols Shared Services North America, Inc.$583
- Shionogi Inc$246
- Paratek Pharmaceuticals, Inc.$56
What the payments were for
- Consulting fees$21,7825%
- Speaking & faculty fees$326,71676%
- Travel & lodging$69,18216%
- Food & beverage$10,6482%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Grifols USA, LLC | 536 | $365,185 |
| Sanofi Pasteur Inc. | 62 | $48,964 |
| Pfizer | 21 | $13,293 |
| Grifols Shared Services North America, Inc. | 7 | $583 |
| Shionogi Inc | 2 | $246 |
| Paratek Pharmaceuticals, Inc. | 1 | $56 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- HyperRAB$290,883
- HyperRAB SD$68,103
- HyperTET SD$66,503
- HyperTET$34,853
- FLUZONE HIGH-DOSE$26,233
- FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE$11,911
- TRUMENBA$7,712
- FLUBLOK QUADRIVALENT$6,671
- FLUZONE QUADRIVALENT$4,818
- MENQUADFI$3,059
- PREVNAR - 13$2,639
- PREVNAR 20$2,590
- Fetroja$246
How this compares
$428,328 in reported general payments places this provider in the 95th percentile of 159 infectious disease providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other infectious disease in Meriden
- Zane SaulStratford$513K
- Onyema OgbuaguNew Haven$412K
- David RubinNorwalk$397K
- Steven SchnittmanWest Haven$363K
- Kalpana GuptaWest Haven$160K
- Frederick AlticeNew Haven$143K
- Paul AnthonyHartford$91K
- Adrian DemidontHamden$90K
- Albert KoNew Haven$43K
- Richard SuttonWest Haven$34K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.